Recent studies have focused on the overlap of GLP|GIP|glucagon receptor activator therapies and dopamine neurotransmission. While GLP stimulators are increasingly employed for managing type 2 diabetes, their unexpected https://ll37228146.widblog.com/96710725/emerging-glp-stimulators-and-dopaminergic-modulation-a-comparative-examination